These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9845393)

  • 41. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 42. Spinal and epidural hematoma and low-molecular-weight heparin.
    Wysowski DK; Talarico L; Bacsanyi J; Botstein P
    N Engl J Med; 1998 Jun; 338(24):1774-5. PubMed ID: 9625640
    [No Abstract]   [Full Text] [Related]  

  • 43. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 44. [Thromboprophylaxis and neuroaxial anesthesia: watch carefully to prevent adverse effects].
    Horlocker TT
    Rev Esp Anestesiol Reanim; 2001; 48(6):255-7. PubMed ID: 11446939
    [No Abstract]   [Full Text] [Related]  

  • 45. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 47. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

  • 48. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How many deaths occur annually from adverse drug reactions in the United States?
    Chyka PA
    Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spinal or epidural anaesthesia with low molecular weight heparin for thromboprophylaxis requires careful postoperative neurological observation.
    Modig J
    Acta Anaesthesiol Scand; 1992 Oct; 36(7):603-4. PubMed ID: 1332354
    [No Abstract]   [Full Text] [Related]  

  • 51. MEDWATCH: the new FDA medical products reporting program.
    Kennedy DL
    Respir Care; 1993 Oct; 38(10):1077-80. PubMed ID: 10145891
    [No Abstract]   [Full Text] [Related]  

  • 52. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 53. MedWatch, the new FDA adverse effects reporting system.
    Shader RI; Greenblatt DJ
    J Clin Psychopharmacol; 1993 Oct; 13(5):303-4. PubMed ID: 8227487
    [No Abstract]   [Full Text] [Related]  

  • 54. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 55. Xyrem (sodium oxybate) postmarketing adverse event reporting system.
    Wang YG
    Sleep Med; 2010 Jun; 11(6):595; author reply 595-6. PubMed ID: 20362501
    [No Abstract]   [Full Text] [Related]  

  • 56. A primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data.
    Allan MC
    J Pharm Technol; 1992; 8(6):259-73. PubMed ID: 10122649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reporting of adverse events to MedWatch.
    Piazza-Hepp TD; Kennedy DL
    Am J Health Syst Pharm; 1995 Jul; 52(13):1436-9. PubMed ID: 7671043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FDA's MedWatch Program Monitors Drug Safety, But It Depends on Nurses to Report Adverse Events.
    Miller D
    ONS Connect; 2015 Sep; 30(3):49. PubMed ID: 26449124
    [No Abstract]   [Full Text] [Related]  

  • 59. FDA post-marketing safety decisions.
    Klein DF
    J Clin Psychiatry; 2006 Aug; 67(8):1305-6. PubMed ID: 16965212
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatch.
    Smith KM; Lawson AP; Tuteja S
    Am J Health Syst Pharm; 2006 May; 63(10):949-52. PubMed ID: 16675652
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.